STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 102491

To: Lisa V Cook	**From:** Beverly Shears
Location: CM1-7E12	**Location:** Biotech-Chem Library CM1-1E05
Art Unit: 1641	**Phone:** 308-4994
Friday, August 29, 2003	beverly.shears@uspto.gov
Case Serial Number: 09/845738	

Search Notes

Cook, L.
09184573 8

FILE 'REGISTRY' ENTERED AT 08:58:43 ON 29 AUG 2003
L1 31 S ITHRIHWESASLL/SQSP

FILE 'HCAPLUS' ENTERED AT 08:58:57 ON 29 AUG 2003
L2 22 S L1

L2 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:454611 HCAPLUS
DOCUMENT NUMBER: 139:35061
TITLE: Method for detecting Alzheimer's disease and differentiating Alzheimer's disease from other demential diseases, associated peptides and the use thereof
INVENTOR(S): Lamping, Norbert; Zucht, Hans-Dieter; Selle, Hartmut; Juergens, Michael; Heine, Gabriele; Hess, Ruediger
PATENT ASSIGNEE(S): Biovision Ag, Germany
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048775	A2	20030612	WO 2002-DE4360	20021127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2001-10158180 A 20011128

AB The invention relates to defined peptides and the quant. detn. thereof in the body fluids of patients suffering from Alzheimer's disease in relation to the concn. thereof in a control group of patients who are healthy or suffer from other demential diseases. The inventive peptides originate from the C3f fragment of the complement C3 protein precursor with the corresponding gene and are modified in a specific manner and are optionally post-translationally or chem. modified. Modification occurs with respect to the concns. of said peptides in patients in a manner which is specific to each peptide when compared with the control group. A specific and significant modification of the concn. of said peptides in relation to the concn. thereof in healthy persons indicates a differentiation with respect to Alzheimer's disease. The invention also relates to the use of said peptides as a progress control, and in the development of diagnostic and therapeutic agents.

IT **112805-24-0**, Complement C3f (human) **473546-15-5** **473546-71-3** **473552-36-2** **473552-58-8** **474451-12-2** **474451-15-5** **474451-16-6**

RL: ANT (Analyte); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f peptides in diagnosis and therapy of Alzheimer's disease)

IT **542823-22-3**
RL: PRP (Properties)
(unclaimed protein sequence; method for detecting Alzheimer's disease and differentiating Alzheimer's disease from other demential diseases, assocd. peptides and the use thereof)

L2 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:849924 HCAPLUS
DOCUMENT NUMBER: 137:348844
TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall, John
PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088727	A2	20021107	WO 2002-CA617	20020429
WO 2002088727	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002169278	A1	20021114	US 2001-845730	20010430
US 6593298	B2	20030715		

PRIORITY APPLN. INFO.: US 2001-845730 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT **473552-58-8**
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(biopolymer marker indicative of disease state having a mol. wt. of 1690 daltons)

L2 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:849922 HCAPLUS
DOCUMENT NUMBER: 137:348843
TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088717	A2	20021107	WO 2002-CA578	20020425

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845736 A 20010430
AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.
IT **112805-24-0**, Complement C3f (human)
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(biopolymer marker indicative of disease state having a mol. wt. of 2056 daltons)

L2 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:833550 HCAPLUS
DOCUMENT NUMBER: 137:334910
TITLE: Complement C3f biopolymer marker indicative of myocardial infarction and congestive heart failure having a molecular weight of 1865 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161182	A1	20021031	US 2001-846345	20010430
WO 2002088174	A2	20021107	WO 2002-CA622	20020429
WO 2002088174	A3	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846345 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SSKITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1865 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, Type II diabetes, or congestive heart failure.

IT **473546-71-3**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 1865 daltons indicative of myocardial infarction and congestive heart failure)

L2 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:833549 HCAPLUS
DOCUMENT NUMBER: 137:334909
TITLE: Complement C3f biopolymer marker indicative of myocardial infarction and congestive heart failure having a molecular weight of 2021 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161181	A1	20021031	US 2001-846344	20010430
WO 2002088711	A2	20021107	WO 2002-CA627	20020429
WO 2002088711	A3	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846344 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SSKITHRIHWESASLLR and characterized as a complement C3f fragment having a mol. wt. of 2021 daltons was found. This marker is indicative of myocardial infarction, Type II diabetes, or congestive heart failure.

IT **112805-24-0**, Complement C3f (human)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 2021 daltons indicative of myocardial infarction and congestive heart failure)

L2 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:833429 HCAPLUS
DOCUMENT NUMBER: 137:334903
TITLE: Complement C3f biopolymer marker indicative of Type II diabetes having a molecular weight of 1998 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160532	A1	20021031	US 2001-846346	20010430
WO 2002088707	A2	20021107	WO 2002-CA616	20020429

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846346 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SSKITHRIHWESASLLR and characterized as a complement C3f fragment having a mol. wt. of 1998 daltons was found. This marker is indicative of Type II diabetes.

IT **112805-24-0**, Complement C3f (human)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 1998 daltons indicative of type II diabetes)

L2 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:833426 HCAPLUS
DOCUMENT NUMBER: 137:334902
TITLE: Complement C3f biopolymer marker indicative of myocardial infarction or congestive heart failure having a molecular weight of 1562 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall, John
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2002160529 A1 20021031 US 2001-845738 20010430
WO 2002088729 A2 20021107 WO 2002-CA629 20020429
WO 2002088729 A3 20021227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-845738 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence ITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1562 daltons was found. This marker is indicative of myocardial infarction or congestive heart failure.

IT **473552-36-2**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 1562 daltons indicative of myocardial infarction or congestive heart failure)

L2 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:833402 HCAPLUS
DOCUMENT NUMBER: 137:334900
TITLE: Complement C3f biopolymer marker indicative of myocardial infarction and congestive heart failure having a molecular weight of 1777 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160434	A1	20021031	US 2001-845735	20010430
WO 2002088712	A2	20021107	WO 2002-CA628	20020429

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845735 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SKITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1777 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, Type II diabetes, or congestive heart failure.

IT **473546-15-5**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 1777 daltons indicative of myocardial infarction and congestive heart failure)

L2 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:833395 HCAPLUS
DOCUMENT NUMBER: 137:348834
TITLE: Process for diagnosis of physiological conditions by characterization of proteomic materials
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160420	A1	20021031	US 2001-846330	20010430
WO 2002088744	A2	20021107	WO 2002-CA623	20020429

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846330 A 20010430

AB The present invention discloses the use of proteomic investigation as a diagnostic tool; and particularly teaches the use of proteomic investigative techniques and methodol. to det. a proteomic basis for the development and progression of abnormal physiol. conditions and the development and characterization of risk assessment, diagnostic and therapeutic means and methodologies. Serum samples from patients suffering from a variety of diseases in Syndrome X were analyzed by SELDI mass spectrometry using the Ciphergen PROTEINCHIP system to discern disease markers.

IT **112805-24-0**, Complement C3f (human) **473546-71-3**
474451-12-2 474451-15-5 474451-16-6
RL: PRP (Properties)
(unclaimed sequence; process for diagnosis of physiol. conditions by characterization of proteomic materials)

L2 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:833394 HCAPLUS
DOCUMENT NUMBER: 137:334897
TITLE: Complement C3f biopolymer marker indicative of congestive heart failure having a molecular weight of 1793 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160419	A1	20021031	US 2001-845739	20010430
WO 2002088725	A2	20021107	WO 2002-CA614	20020426
WO 2002088725	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845739 A 20010430

AB The instant invention involves the use of a combination of

preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SKITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1793 daltons was found. This marker is indicative of congestive heart failure.

IT **473546-15-5**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 1793 daltons indicative of congestive heart failure)

L2 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:391912 HCAPLUS
DOCUMENT NUMBER: 137:1836
TITLE: Measurement of DNA methylation for analysis of the toxicology of substances
INVENTOR(S): Olek, Alexander; Piepenbrock, Christian; Berlin, Kurt
PATENT ASSIGNEE(S): Epigenomics Ag, Germany
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040710	A2	20020523	WO 2001-EP12951	20011108
WO 2002040710	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056802	A1	20020529	DE 2000-10056802	20001114
AU 2002023672	A5	20020527	AU 2002-23672	20011108
EP 1337668	A2	20030827	EP 2001-996625	20011108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: DE 2000-10056802 A 20001114
WO 2001-EP12951 W 20011108

AB The invention relates to a method for anal. of the toxicol. of a substance by measuring its effects using changes in DNA methylation as an indicator of toxicol. According to the invention, a DNA sample is taken from an organism or a cell culture which has been exposed to a specific substance which is to be examd. on account of its toxicol. effect. The DNA contained in said sample is chem. pre-treated and the base sequence of a section of the modified DNA is detd. The preferred method is to convert cytosine in CpG dinucleotides to uracil using bisulfite. Probes specific for cytosine- or uracil-contg. DNA can be used to detect changes in methylation. From there, a characteristic methylation state or a characteristic methylation model is detd. for the sample. By comparison with data from methylation states of other samples, the effect of a substance on the organism or the cell culture is detd. and/or compared to other substances in toxicol. terms. A panel of sequences that can be used to analyze the effects of poisons is described.

IT **391975-41-0**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; measurement of DNA methylation for anal. of the toxicol. of substances)

L2 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:72748 HCAPLUS
DOCUMENT NUMBER: 136:146104
TITLE: Human stress genes identified using DNA microarrays
INVENTOR(S): Chenchik, Alex; Lukashev, Matvey E.
PATENT ASSIGNEE(S): Clontech, USA
SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 441,920.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002009730	A1	20020124	US 2001-782909	20010213
PRIORITY APPLN. INFO.:			US 1998-222256 B2	19981228
			US 1999-440305 B2	19991117
			US 1999-441920 A2	19991117

AB Human stress arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe compn. of unique polynucleotides corresponding to a human stress gene. The av. length of the polynucleotide probes is between 50 to 1000 nucleotides. The d. of the spots on the array did not exceed 400/cm2 and the spots had a diam. ranging between 10 to 5000 .mu.m. Furthermore, the no. of polynucleotide probe spots on the array ranged between 50 to 2000 nucleotides. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes. 236 Different human stress genes were identified using this approach.

IT **391975-41-0**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; human stress genes identified using DNA microarrays)

L2 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:872086 HCAPLUS
DOCUMENT NUMBER: 136:32768
TITLE: Nucleic acids and their encoded polypeptides from human tissues
INVENTOR(S): Tang, Y. Tom; Liu, Chenghua; Drmanac, Radoje T.
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 831 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 82
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001088088	A2	20011122	WO 2001-XB14827	20010516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001088088	A2	20011122	WO 2001-US14827	20010516
WO 2001088088	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-577408 A 20000518
WO 2001-US14827 W 20010516

AB The present invention provides a collection or library of 8051 nucleic acid contig sequences assembled from expressed sequence tag or cDNA libraries isolated mainly by sequencing by hybridization (SBH), std. PCR, Sanger sequencing techniques, and in some cases, sequences obtained form one or more public databases. The cDNA libraries are from human tissue sources and nearest neighbor sequence homologies are provided. The invention also relates to the proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. [This abstr. record is one of four records for this

document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **375916-77-1**
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)

L2 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:828435 HCAPLUS
DOCUMENT NUMBER: 137:42609
TITLE: Human nucleic acids and polypeptides and their diagnostic and therapeutic uses
INVENTOR(S): Drmanac, Rodoje T.; Liu, Chenghua; Tang, Y. Tom
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 82
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001075067	A2	20011011	WO 2001-XA8631	20010330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001075067	A2	20011011	WO 2001-US8631	20010330
WO 2001075067	A3	20020404		
WO 2001075067	C2	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
US 2000-540217 A 20000331
US 2000-649167 A 20000823
WO 2001-US8631 W 20010330

AB The present invention provides 30,368 nucleic acids and the 30,368 novel human polypeptide sequences encoded by these nucleic acids. A plurality of novel nucleic acids are obtained from cDNA libraries prepd. from various human tissues and in some cases isolated from a

genomic library derived from human chromosomes using std. PCR, sequencing by hybridization signature anal., and Sanger sequencing techniques. Nearest neighbor results are identified by sequence homol. searching. The invention also relates to therapeutic, diagnostic, and research utilities for these polynucleotides and proteins. [This abstr. record is one of 10 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **437833-34-6**
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; human nucleic acids and polypeptides and their diagnostic and therapeutic uses)

L2 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:798427 HCAPLUS
DOCUMENT NUMBER: 135:353806
TITLE: Human G protein-coupled receptor-like MOLX proteins and the nucleic acids that encode them
INVENTOR(S): Vernet, Corine A. M.; Fernandes, Elma R.; Gerlach, Valerie; Shimkets, Richard A.; Malyankar, Uriel M.; Boldog, Ferenc L.; Zerhusen, Bryan D.; Spytek, Kimberly A.; Majumder, Kumud; Tchernev, Velizar T.; Padigaru, Muralidhara; Patturajan, Meera; Burgess, Catherine E.; Gangolli, Esha A.; Smithson, Glennda; Rastelli, Luca; MacDougall, John R.; Taupier, Raymond J., Jr.; Grosse, William M.; Szekeres, Edward S., Jr.; Alsoborook, John P., II
PATENT ASSIGNEE(S): Curagen Corp., USA
SOURCE: PCT Int. Appl., 227 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081578	A2	20011101	WO 2001-US13578	20010426
WO 2001081578	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003083244	A1	20030501	US 2001-842758	20010425
EP 1309683	A2	20030514	EP 2001-928927	20010426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:

US 2000-200158P	P	20000426
US 2000-200780P	P	20000428
US 2000-201006P	P	20000501
US 2000-201007P	P	20000501
US 2000-201236P	P	20000501
US 2000-201238P	P	20000502
US 2000-201474P	P	20000503
US 2000-201508P	P	20000503
US 2000-220591P	P	20000725
US 2000-232678P	P	20000915
US 2001-263217P	P	20010122
US 2001-265160P	P	20010130
US 2000-200613P	P	20000428
US 2000-201186P	P	20000502
WO 2001-US13578	W	20010426

AB Disclosed herein are 15 nucleic acid sequences that encode human G protein-coupled receptor-related polypeptides, designated MOL1 to MOL10b. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. Nearest neighbor sequence homologies, protein domains, tissue expression profiles, and chromosomal location are also provided. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

IT **372124-35-1**
RL: PRP (Properties)
(unclaimed sequence; human G protein-coupled receptor-like MOLX proteins and the nucleic acids that encode them)

L2 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:618207 HCAPLUS
DOCUMENT NUMBER: 135:190398
TITLE: Nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers
INVENTOR(S): Roth, Frederick P.; Van Huffel, Christophe; White, James V.; Shyjan, Andrew W.
PATENT ASSIGNEE(S): Millennium Predictive Medicine, Inc., USA
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001061048	A2	20010823	WO 2001-US5263	20010216
WO 2001061048	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002051978 A1 20020502 US 2001-788100 20010216

PRIORITY APPLN. INFO.: US 2000-183312P P 20000217

AB The present invention is directed to the identification of markers that can be used to det. the sensitivity of cancer cells to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. Nucleic acid arrays were used to det. the level of expression of sequences (genes) found in 60 different solid tumor cancer cell lines selected form the NCI 60 cancer cell line series. Expression anal. was used to identify markers assocd. with sensitivity to certain chemotherapeutic agents.

IT **355485-87-9**

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)

L2 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:618196 HCAPLUS

DOCUMENT NUMBER: 127:261706

TITLE: Down-regulation resistant C3 convertase

INVENTOR(S): Farries, Timothy Charles; Harrison, Richard Alexander

PATENT ASSIGNEE(S): Imutran Ltd., UK; Farries, Timothy Charles; Harrison, Richard Alexander

SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732981	A1	19970912	WO 1997-GB603	19970304
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2247615	AA	19970912	CA 1997-2247615	19970304
AU 9722257	A1	19970922	AU 1997-22257	19970304
AU 726187	B2	20001102		
EP 885301	A1	19981223	EP 1997-905334	19970304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
CN 1214733	A	19990421	CN 1997-193318	19970304
BR 9708005	A	20000104	BR 1997-8005	19970304
NZ 331595	A	20000228	NZ 1997-331595	19970304

JP 2000515001	T2	20001114	JP 1997-531570	19970304
ZA 9701900	A	19980907	ZA 1997-1900	19970305
NO 9804073	A	19981102	NO 1998-4073	19980904
US 6268485	B1	20010731	US 1999-142334	19990415
US 2002068059	A1	20020606	US 2001-875519	20010606

PRIORITY APPLN. INFO.:

GB 1996-4865	A	19960307
GB 1996-11896	A	19960607
GB 1996-14293	A	19960708
GB 1996-24028	A	19961119
WO 1997-GB603	W	19970304
US 1999-142334	A3	19990415

AB Native complement pathway proteins modified such that the protein is capable of forming a down-regulation resistant C3 convertase. Preferably the modified protein is a modified human C3 protein. DNA sequences encoding such proteins are also provided, together with DNA constructs. Conjugates comprising such proteins and a specific binding moiety, for example an antibody, are also described, as are uses of such proteins and/or conjugates in therapy (such as preventing rejection of foreign matter). Mutant human C3 proteins with Arg residue(s) replaced by Glu at position 1303, 1320, and both 1303 and 1320 were prepd. and tested for resistance to C3 convertase and factor I.

IT **178359-66-5**, Complement C3, prepro- (human clone PC3) **178359-68-7**, Complement C3, prepro- [1303-glutamic acid] (human clone PC3) **178359-73-4**, Complement C3, prepro- [752-glycine,753-serine,754-glycine,758-glycine,759-serine,760-glycine] (human clone PC3) **196318-72-6 196318-73-7**
RL: PRP (Properties)
(amino acid sequence; prepn. of mutant human C3 complement proteins resistant to C3 convertase or factor I or H for preventing rejection of foreign matter)

L2 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	1996:404866 HCAPLUS
DOCUMENT NUMBER:	125:51929
TITLE:	Modified human C3 proteins capable of forming stable C3 convertases and their used in pharmaceuticals
INVENTOR(S):	Harrison, Richard Alexander; Farries, Timothy Charles
PATENT ASSIGNEE(S):	Imutran Limited, UK
SOURCE:	PCT Int. Appl., 80 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9607738	A2	19960314	WO 1995-GB2121	19950908
WO 9607738	A3	19960328		

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM

RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,

	MR, NE, SN, TD, TG				
CA 2197888		AA	19960314	CA 1995-2197888	19950908
AU 9534772		A1	19960327	AU 1995-34772	19950908
AU 707004		B2	19990701		
EP 779922		A2	19970625	EP 1995-931276	19950908
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1162335		A	19971015	CN 1995-194984	19950908
CN 1104501		B	20030402		
BR 9509172		A	19971125	BR 1995-9172	19950908
JP 10505241		T2	19980526	JP 1995-509319	19950908
HU 77874		A2	19980928	HU 1998-775	19950908
NZ 333949		A	20000623	NZ 1995-333949	19950908
RO 117189		B1	20011130	RO 1997-417	19950908
CZ 290596		B6	20020814	CZ 1997-685	19950908
RU 2194713		C2	20021220	RU 1997-105374	19950908
US 5849297		A	19981215	US 1997-793126	19970207
FI 9700979		A	19970307	FI 1997-979	19970307
NO 9701059		A	19970507	NO 1997-1059	19970307
BG 63606		B1	20020628	BG 1997-101295	19970307
US 6221657		B1	20010424	US 1998-132271	19980811

PRIORITY APPLN. INFO.:	GB 1994-18147	A	19940908
	GB 1995-9102	A	19950504
	NZ 1995-292565	A1	19950908
	WO 1995-GB2121	W	19950908
	US 1997-793126	A3	19970207

AB Native complement pathway proteins modified such that the protein is capable of forming a stable C3 convertase are claimed. Preferably the modified protein is a modified human C3 protein. DNA sequences encoding such proteins are also provided, together with DNA constructs. Conjugates comprising such proteins and a specific binding moiety, for example an antibody, are also described, as are uses of such proteins and/or conjugates in therapy. Various complement C3 variants were prepd. with recombinant COS cells and their resistance to Factor H and/or Factor I demonstrated. Another variant resistant to Factor B was also prepd. One variant conjugated to anti-erythrocyte IgG was produced and shown to target C3 convertase activity to erythrocytes. Variant complement C3 was shown to induce turnover of Factor B in human serum.

IT **178359-75-6**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequence, diminished interaction with Factor B of; modified human C3 proteins capable of forming stable C3 convertases and their used in pharmaceuticals)

IT **178359-67-6 178359-68-7 178359-69-8**
178359-70-1 178359-71-2 178359-72-3
178359-73-4 178359-74-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequence; modified human C3 proteins capable of forming stable C3 convertases and their used in pharmaceuticals)

IT **178359-66-5**, Complement C3, prepro- (human clone PC3)
RL: PRP (Properties)
(amino acid sequence; modified human C3 proteins capable of forming stable C3 convertases and their used in pharmaceuticals)

L2 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1993:537093 HCAPLUS
DOCUMENT NUMBER: 119:137093
TITLE: Disulfide bridges in human complement component C3b
AUTHOR(S): Dolmer, Klavs; Sottrup-Jensen, Lars
CORPORATE SOURCE: Dep. Mol. Biol., Univ. Aarhus, Aarhus, 8000, Den.
SOURCE: FEBS Letters (1993), 315(1), 85-90
CODEN: FEBLAL; ISSN: 0014-5793
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The disulfide bridges of human complement component C3b, derived from C3 by removal of the 77-residue C3a, were detd. The 10 bridges are Cys537-Cys794, Cys605-Cys640, Cys851-Cys1491, Cys1079-Cys1136, Cys1336-Cys1467, Cys1367-Cys1436, Cys1484-Cys1489, Cys1496-Cys1568, Cys1515-Cys1639, and Cys1615-Cys1624. Including the 3 bridges in C3a (Cys670-Cys698, Cys672-Cys705, and Cys685-Cys706) previously detd. by high-resoln. x-ray crystallog., all disulfide bridges of C3 are localized. C3 and the related C4 and C5 are members of the .alpha.2-macroglobulin superfamily. The predicted bridge patterns of C4 and C5 are discussed and compared with that of .alpha.2-macroglobulin.

IT **149748-47-0**
RL: PRP (Properties)
(amino acid sequence of, complete)

L2 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1990:53423 HCAPLUS
DOCUMENT NUMBER: 112:53423
TITLE: Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized
AUTHOR(S): Ganu, Vishwas S.; Mueller-Eberhard, Hans J.; Hugli, Tony E.
CORPORATE SOURCE: Pharm. Div., CIBA-GEIGY Corp., Summit, NJ, 07901, USA
SOURCE: Molecular Immunology (1989), 26(10), 939-48
CODEN: MOIMD5; ISSN: 0161-5890
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Complement C3f, a heptadeca-peptide having the amino acid sequence of Ser-Ser-Lys-Ile-Thr-His-Arg-Ile-His-Trp-Glu-Ser-Ala-Ser-Leu-Leu-Arg, is liberated during the catabolic degrdn. of C3b in serum. The amino acid sequence of C3f is known both from the cDNA-derived structure of C3 and from protein anal. after isolation of the natural factor. C3f was synthesized by solid phase peptide synthesis. Both natural and synthetic C3f had identical retention times by RP-18 HPLC anal. and the resp. amino acid compns. agreed with the expected theor. values. C3f, but not des-Arg-C3f, was weakly spasmogenic, inducing contraction of guinea pig ileum at a level of 5-10 .times. 10-6M. Since C3f and C3a were cross-tachyphylactic, it was concluded that these 2 spasmogens compete for the same receptors. Both C3f and des-Arg-C3f at concns. of 1-4 .times. 10-4M enhanced vascular permeability in guinea pig skin. These observations further suggest that C3f functionally resembles C3a anaphylatoxin. Formation of C3f in human serum following activation of C3 could be demonstrated by RIA. Digestion

of C3f with purified human serum carboxypeptidase N produced C3f-desArg. Thus, when serum complement protein C3 undergoes conversion to C3b, further degrdn. by factors H and I readily generates C3f. C3f is a weak spasmogen that functions like C3a anaphylatoxin and C3f-desArg is a major metabolite in serum.

IT **124882-78-6P**
RL: PREP (Preparation)
(prepn. and C3a anaphylatoxin properties of)

L2 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1988:73458 HCAPLUS
DOCUMENT NUMBER: 108:73458
TITLE: Structure of C3f, a small peptide specifically released during inactivation of the third component of complement
AUTHOR(S): Harrison, Richard A.; Farries, Timothy C.; Northrop, Frederick D.; Lachmann, Peter J.; Davis, Alvin E.
CORPORATE SOURCE: Lab. Mol. Biol., MRC Cent., Cambridge, UK
SOURCE: Complement (1987), 5(1), 27-32
CODEN: CMPLDF; ISSN: 0253-5076
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Complement C3f, a peptide presumed to be generated by the combined actions of human factors I and H on fluid-phase C3b, has been isolated and sequenced. The peptide is 17 residues long and has a mol. wt. of 1847 daltons. The N-terminal sequence is, with the exception of a single residue, identical to that deduced for the 46-kilodalton polypeptide seen transiently in the generation of iC3b from C3b, and is in full agreement with the sequence deduced from cDNA anal. In addn., HPLC of the digestion of C3b by factor I has shown that C3f is the sole peptide released during iC3b generation.

IT **112805-24-0**
RL: PRP (Properties)
(amino acid sequence of)

L2 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1985:180051 HCAPLUS
DOCUMENT NUMBER: 102:180051
TITLE: Human complement component C3: cDNA coding sequence and derived primary structure
AUTHOR(S): De Bruijn, Maarten H. L.; Fey, Georg H.
CORPORATE SOURCE: Res. Inst., Scripps Clin., La Jolla, CA, 92037, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1985), 82(3), 708-12
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The complete cDNA coding sequence and derived amino acid sequence of human complement C3 [80295-41-6] are presented. The encoded precursor mol. contains a signal peptide of 22 amino acid residues, the .beta. chain (645 residues), and the .alpha. chain (992 residues). The 2 chains are joined by 4 arginine residues not present in the mature protein. Several functionally important sites have been localized, such as the thiolester site, the cleavage site liberating the anaphylatoxin, and 2 sites of cleavage by the serine

protease factor I, as well as a peptide fragment with leukocyte mobilizing activity. At least 2 carbohydrate attachment sites, 1 on each chain, have been identified. Human C3 has 79% identity to mouse C3 at the nucleotide level and 77% identity at the amino acid level. The protease .alpha.2-macroglobulin and complement component C4 show considerable homol. to C3, suggesting that the 3 proteins have evolved from a common ancestor.

IT **96162-40-2 96162-41-3 96162-42-4**
RL: PRP (Properties)
(amino acid sequence of)

E1 THROUGH E31 ASSIGNED

FILE 'REGISTRY' ENTERED AT 08:59:42 ON 29 AUG 2003

L3 31 SEA FILE=REGISTRY ABB=ON PLU=ON (112805-24-0/BI OR 473546-15-5/BI OR 473546-71-3/BI OR 178359-66-5/BI OR 178359-68-7/BI OR 178359-73-4/BI OR 391975-41-0/BI OR 473552-36-2/BI OR 473552-58-8/BI OR 474451-12-2/BI OR 474451-15-5/BI OR 474451-16-6/BI OR 124882-78-6/BI OR 149748-47-0/BI OR 178359-67-6/BI OR 178359-69-8/BI OR 178359-70-1/BI OR 178359-71-2/BI OR 178359-72-3/BI OR 178359-74-5/BI OR 178359-75-6/BI OR 196318-72-6/BI OR 196318-73-7/BI OR 355485-87-9/BI OR 372124-35-1/BI OR 375916-77-1/BI OR 437833-34-6/BI OR 542823-22-3/BI OR 96162-40-2/BI OR 96162-41-3/BI OR 96162-42-4/BI)

L4 31 L3 AND L1

L4 ANSWER 1 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **542823-22-3** REGISTRY
CN 1: PN: WO03048775 SEQID: 17 unclaimed protein (9CI) (CA INDEX NAME)
CI MAN
SQL 1255

SEQ
```
  1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
 51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
301 VLSRKVLLDG VQNLRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFQQLA
651 FRQPSSAFAA FVKRAPSTWL TAYVVKVFSL AVNLIAIDSQ VLCGAVKWLI
701 LEKQKPDGVF QEDAPVIHQE MIGGLRNNNE KDMALTAFVL ISLQEAKDIC
751 EEQVNSLPGS ITKAGDFLEA NYMNLQRSYT VAIAGYALAQ MGRLKGPLLN
801 KFLTTAKDKN RWEDPGKQLY NVEATSYALL ALLQLKDFDF VPPVVRWLNE
851 QRYYGGGYGS TQATFMVFQA LAQYQKDAPD HQELNLDVSL QLPSRSSKIT
                                                        ==
901 HRIHWESASL LRSEETKENE GFTVTAEGKG QGTLSVVTMY HAKAKDQLTC
    ========== =
951 NKFDLKVTIK PAPETEKRPQ DAKNTMILEI CTRYRGDQDA TMSILDISMM
1001 TGFAPDTDDL KQLANGVDRY ISKYELDKAF SDRNTLIIYL DKVSHSEDDC
```

1051 LAFKVHQYFN VELIQPGAVK VYAYYNLEES CTRFYHPEKE DGKLNKLCRD
1101 ELCRCAEENC FIQKSDDKVT LEERLDKACE PGVDYVYKTR LVKVQLSNDF
1151 DEYIMAIEQT IKSGSDEVQV GQQRTFISPI KCREALKLEE KKHYLMWGLS
1201 SDFWGEKPNL SYIIGKDTWV EHWPEEDECQ DEENQKQCQD LGAFTESMVV
1251 FGCPN
HITS AT: 899-911

REFERENCE 1: 139:35061

L4 ANSWER 2 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **474451-16-6** REGISTRY
CN L-Arginine, L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 15: PN: US20020160420 PAGE: 16 unclaimed sequence
CN 7: PN: WO03048775 SEQID: 7 claimed sequence
SQL 16

SEQ 1 SKITHRIHWE SASLLR
========= =====
HITS AT: 3-15

REFERENCE 1: 139:35061

REFERENCE 2: 137:348834

L4 ANSWER 3 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **474451-15-5** REGISTRY
CN L-Arginine, L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 14: PN: US20020160420 PAGE: 15 unclaimed sequence
CN 9: PN: WO03048775 SEQID: 9 claimed sequence
SQL 15

SEQ 1 KITHRIHWES ASLLR
========== ====
HITS AT: 2-14

REFERENCE 1: 139:35061

REFERENCE 2: 137:348834

L4 ANSWER 4 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **474451-12-2** REGISTRY
CN L-Arginine, L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 11: PN: WO03048775 SEQID: 11 claimed sequence
CN 9: PN: US20020160420 PAGE: 13 unclaimed sequence
SQL 14

SEQ 1 ITHRIHWESA SLLR
========== ===
HITS AT: 1-13

REFERENCE 1: 139:35061

REFERENCE 2: 137:348834

L4 ANSWER 5 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **473552-58-8** REGISTRY
CN L-Leucine, L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 10: PN: WO03048775 SEQID: 10 claimed sequence
CN 1: PN: WO02088727 SEQID: 1 claimed protein
SQL 14

SEQ 1 KITHRIHWES ASLL
========= ====
HITS AT: 2-14

REFERENCE 1: 139:35061

REFERENCE 2: 137:348844

L4 ANSWER 6 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **473552-36-2** REGISTRY
CN L-Leucine, L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: WO03048775 SEQID: 12 claimed sequence
CN 1: PN: US20020160529 PAGE: 7 claimed protein
SQL 13

SEQ 1 ITHRIHWESA SLL
========== ===
HITS AT: 1-13

REFERENCE 1: 139:35061

REFERENCE 2: 137:334902

L4 ANSWER 7 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **473546-71-3** REGISTRY
CN L-Leucine, L-seryl-L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20020161182 PAGE: 7 claimed protein
CN 20: PN: US20020160420 PAGE: 20 unclaimed sequence
CN 2: PN: WO03048775 SEQID: 2 claimed sequence
SQL 16

SEQ 1 SSKITHRIHW ESASLL
======= ======
HITS AT: 4-16

REFERENCE 1: 139:35061

REFERENCE 2: 137:348834

REFERENCE 3: 137:334910

L4 ANSWER 8 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **473546-15-5** REGISTRY
CN L-Leucine, L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20020160419 PAGE: 7 claimed protein
CN 1: PN: US20020160434 PAGE: 7 claimed protein
CN 8: PN: WO03048775 SEQID: 8 claimed sequence
SQL 15

SEQ 1 SKITHRIHWE SASLL
========= =====
HITS AT: 3-15

REFERENCE 1: 139:35061

REFERENCE 2: 137:334900

REFERENCE 3: 137:334897

L4 ANSWER 9 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **437833-34-6** REGISTRY
CN Protein (human clone WO0175067-SEQID-56335) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2288: PN: WO0175067 SEQID: 56335 claimed protein
CI MAN
SQL 1540

SEQ
1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
301 VLSRKVLLDG VQNLRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI
901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP

```
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVELIPRL
                ==== =========
      1351 GGQFKVYAYY NLEESCTRFY HPEKEDGKLN KLCRDELCRC AEENCFIQKS
      1401 DDKVTLEERL DKACEPGVDY VYKTRLVKVQ LSNDFDEYIM AIEQTIKSGS
      1451 DEVQVGQQRT FISPIKCREA LKLEEKKHYL MWGLSSDFWG EKPNLSYIIG
      1501 KDTWVEHWPE EDECQDEENQ KQCQDLGAFT ESMVVFGCPN
HITS AT:   1307-1319

REFERENCE   1:  137:42609

L4   ANSWER 10 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   391975-41-0  REGISTRY
CN   Complement component C3 (human clone pC3.[11,49,59]. gene C3) (9CI)
     (CA INDEX NAME)
OTHER NAMES:
CN   GenBank AAA85332
CN   GenBank AAA85332 (Translated from: GenBank K02765)
CI   MAN
SQL  1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNLRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:   1307-1319
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:1836

REFERENCE 2: 136:146104

L4 ANSWER 11 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **375916-77-1** REGISTRY
CN Protein (human clone WO0188088-SEQID-10528 fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2477: PN: WO0188088 SEQID: 10528 claimed protein
CI MAN
SQL 1609

SEQ
1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
301 VLSRKVLLDG VQNLRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI
901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
==== =========
1351 KAKDQLTCNK FDLKAAGPMV LTDTSPSMSL DKAFSDRNTL IIYLDKVSHS
1401 EDDCLAFKVH QYFNVELIQP GAVKVYAYYN LEESCTRFYH PEKEDGKLNK
1451 LCRDELCRCA EENCFIQKSD DKVTLEERLD KACEPGVDYV YKNRLVKVQL
1501 SNDFDEYIMA IEQTIKSGSD EVQVGQQRTF ISPIKCREAL KLEEKKHYLM
1551 WGLSSDFWGE KPNLSYIIGK DTWVEHWPEE DECQDEENQK QCQDLGAFTE
1601 SMVVFGCPN
HITS AT: 1307-1319

REFERENCE 1: 136:32768

L4 ANSWER 12 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **372124-35-1** REGISTRY
CN 1: PN: WO0181578 PAGE: 29-32 unclaimed sequence (9CI) (CA INDEX NAME)
CI MAN

SQL 1663

```
SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDLPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNLRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGDRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319

REFERENCE   1:  135:353806

L4    ANSWER 13 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN    355485-87-9  REGISTRY
CN    Complement C 3 (human clone pC3.[11,49,59] gene C3) (9CI)  (CA INDEX
      NAME)
CI    MAN
SQL   1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNLRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
```

```
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  135:190398

L4    ANSWER 14 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN    196318-73-7  REGISTRY
CN    Complement C3, prepro- [1320-glutamic acid] (human clone PC3) (9CI)
      (CA INDEX NAME)
CI    MAN
SQL   1663

SEQ       1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
         51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
        101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
        151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
        201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
        251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
        301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
        351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
        401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
        451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
        501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
        551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
        601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
        651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
        701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
        751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
        801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
        851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
        901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
        951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
```

```
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLE SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:   1307-1319

REFERENCE   1:  127:261706

L4   ANSWER 15 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   196318-72-6  REGISTRY
CN   Complement C3, prepro- [1303-glutamic acid,1320-glutamic acid]
     (human clone PC3) (9CI)  (CA INDEX NAME)
CI   MAN
SQL  1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSESSKITHR IHWESASLLE SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
```

```
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319

REFERENCE   1:  127:261706

L4    ANSWER 16 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN    178359-75-6  REGISTRY
CN    Complement C3, prepro- [1427-glutamine,1431-aspartic
      acid,1433-glutamine] (human clone PC3) (9CI)  (CA INDEX NAME)
CI    MAN
SQL   1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSQSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ====  =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS DYQLDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319

REFERENCE   1:  125:51929

L4    ANSWER 17 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN    178359-74-5  REGISTRY
CN    Complement C3, prepro- [1303-glutamine,1320-glutamine] (human clone
      PC3) (9CI)  (CA INDEX NAME)
CI    MAN
```

SQL 1663

```
SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSQSSKITHR IHWESASLLQ SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319
```

REFERENCE 1: 125:51929

L4 ANSWER 18 OF 31 REGISTRY COPYRIGHT 2003 ACS on STN
RN **178359-73-4** REGISTRY
CN Complement C3, prepro- [752-glycine,753-serine,754-glycine,758-glycine,759-serine,760-glycine] (human clone PC3) (9CI) (CA INDEX NAME)
CI MAN
SQL 1663

```
SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
```

```
         451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
         501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
         551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
         601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
         651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
         701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
         751 LGSGIIAGSG IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
         801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
         851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
         901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
         951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
        1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
        1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
        1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
        1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
        1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
        1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
        1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                   ==== =========
        1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
        1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
        1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
        1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
        1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
        1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
        1651 AFTESMVVFG CPN
HITS AT:    1307-1319

REFERENCE   1:  127:261706

REFERENCE   2:  125:51929

L4    ANSWER 19 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN    178359-72-3  REGISTRY
CN    Complement C3, prepro- [758-glycine,759-serine,760-glycine] (human
      clone PC3) (9CI)  (CA INDEX NAME)
CI    MAN
SQL   1663

SEQ       1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
         51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
        101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
        151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
        201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
        251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
        301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
        351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
        401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
        451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
        501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
        551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
        601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
        651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
        701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
        751 LDEDIIAGSG IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
        801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
        851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
        901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
```

```
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319

REFERENCE   1:  125:51929

L4    ANSWER 20 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN    178359-71-2  REGISTRY
CN    Complement C3, prepro- [752-glycine,753-serine,754-glycine] (human
      clone PC3) (9CI)  (CA INDEX NAME)
CI    MAN
SQL   1663

SEQ       1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
         51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
        101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
        151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
        201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
        251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
        301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
        351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
        401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
        451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
        501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
        551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
        601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
        651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
        701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
        751 LGSGIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
        801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
        851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
        901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
        951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
       1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
       1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
       1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
       1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
       1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
       1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
       1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                 ==== =========
       1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
       1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
       1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
```

```
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:   1307-1319

REFERENCE   1:  125:51929

L4   ANSWER 21 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   178359-70-1  REGISTRY
CN   Complement C3, prepro- [1303-glutamine] (human clone PC3) (9CI)  (CA
     INDEX NAME)
CI   MAN
SQL  1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSQSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:   1307-1319

REFERENCE   1:  125:51929

L4   ANSWER 22 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   178359-69-8  REGISTRY
CN   Complement C3, prepro- [1303-glycine] (human clone PC3) (9CI)  (CA
     INDEX NAME)
```

```
CI   MAN
SQL  1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRGSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== ==========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319

REFERENCE   1:  125:51929

L4   ANSWER 23 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   178359-68-7  REGISTRY
CN   Complement C3, prepro- [1303-glutamic acid] (human clone PC3) (9CI)
     (CA INDEX NAME)
CI   MAN
SQL  1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
```

```
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSESSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== ==========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319

REFERENCE   1:  127:261706

REFERENCE   2:  125:51929

L4    ANSWER 24 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN    178359-67-6  REGISTRY
CN    Complement C3, prepro- [1320-glutamine] (human clone PC3) (9CI)  (CA
      INDEX NAME)
CI    MAN
SQL   1663

SEQ       1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
         51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
        101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
        151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
        201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
        251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
        301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
        351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
        401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
        451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
        501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
        551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
        601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
        651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
        701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
        751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
        801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
        851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
        901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
```

```
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLQ SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:    1307-1319

REFERENCE   1:  125:51929

L4   ANSWER 25 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   178359-66-5  REGISTRY
CN   Complement C3, prepro- (human clone PC3) (9CI)  (CA INDEX NAME)
CI   MAN
SQL  1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTITIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
```

```
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:   1307-1319

REFERENCE   1:  127:261706

REFERENCE   2:  125:51929

L4   ANSWER 26 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   149748-47-0  REGISTRY
CN   Complement C3b (human) (9CI)  (CA INDEX NAME)
CI   MAN
SQL  1560,915,645

SEQ      1 SNLDEDIIAE ENIVSRSEFP ESWLWNVEDL KEPPKNGIST KLMNIFLKDS
        51 ITTWEILAVS MSDKKGICVA DPFEVTVMQD FFIDLRLPYS VVRNEQVEIR
       101 AVLYNYRQNQ ELKVRVELLH NPAFCSLATT KRRHQQTVTI PPKSSLSVPY
       151 VIVPLKTGLQ EVEVKAAVYH HFISDGVRKS LKVVPEGIRM NKTVAVRTLD
       201 PERLGREGVQ KEDIPPADLS DQVPDTESET RILLQGTPVA QMTEDAVDAE
       251 RLKHLIVTPS GCGEQNMIGM TPTVIAVHYL DETEQWEKFG LEKRQGALEL
       301 IKKGYTQQLA FRQPSSAFAA FVKRAPSTWL TAYVVKVFSL AVNLIAIDSQ
       351 VLCGAVKWLI LEKQKPDGVF QEDAPVIHQE MIGGLRNNNE KDMALTAFVL
       401 ISLQEAKDIC EEQVNSLPGS ITKAGDFLEA NYMNLQRSYT VAIAGYALAQ
       451 MGRLKGPLLN KFLTTAKDKN RWEDPGKQLY NVEATSYALL ALLQLKDFDF
       501 VPPVVRWLNE QRYYGGGYGS TQATFMVFQA LAQYQKDAPD HQELNLDVSL
       551 QLPSRSSKIT HRIHWESASL LRSEETKENE GFTVTAEGKG QGTLSVVTMY
                   == ========== =
       601 HAKAKDQLTC NKFDLKVTIK PAPETEKRPQ DAKNTMILEI CTRYRGDQDA
       651 TMSILDISMM TGFAPDTDDL KQLANGVDRY ISKYELDKAF SDRNTLIIYL
       701 DKVSHSEDDC LAFKVHQYFN VELIQPGAVK VYAYYNLEES CTRFYHPEKE
       751 DGKLNKLCRD ELCRCAEENC FIQKSDDKVT LEERLDKACE PGVDYVYKTR
       801 LVKVQLSNDF DEYIMAIEQT IKSGSDEVQV GQQRTFISPI KCREALKLEE
       851 KKHYLMWGLS SDFWGEKPNL SYIIGKDTWV EHWPEEDECQ DEENQKQCQD
       901 LGAFTESMVV FGCPN
HITS AT:   559-571

SEQ      1 SPMYSIITPN ILRLESEETM VLEAHDAQGD VPVTVTVHDF PGKKLVLSSE
        51 KTVLTPATNH MGNVTFTIPA NREFKSEKGR NKFVTVQATF GTQVVEKVVL
       101 VSLQSGYLFI QTDKTIYTPG STVLYRIFTV NHKLLPVGRT VMVNIENPEG
       151 IPVKQDSLSS QNQLGVLPLS WDIPELVNMG QWKIRAYYEN SPQQVFSTEF
       201 EVKEYVLPSF EVIVEPTEKF YYIYNEKGLE VTITARFLYG KKVEGTAFVI
       251 FGIQDGEQRI SLPESLKRIP IEDGSGEVVL SRKVLLDGVQ NLRAEDLVGK
       301 SLYVSATVIL HSGSDMVQAE RSGIPIVTSP YQIHFTKTPK YFKPGMPFDL
       351 MVFVTNPDGS PAYRVPVAVQ GEDTVQSLTQ GDGVAKLSIN THPSQKPLSI
       401 TVRTKKQELS EAEQATRTMQ ALPYSTVGNS NNYLHLSVLR TELRPGETLN
       451 VNFLLRMDRA HEAKIRYYTY LIMNKGRLLK AGRQVREPGQ DLVVLPLSIT
       501 TDFIPSFRLV AYYTLIGASG QREVVADSVM VDVKDSCVGS LVVKSGQSED
       551 RQPVPGQQMT LKIEGDHGAR VVLVAVDKGV FVLNKKNKLT QSKIWDVVEK
       601 ADIGCTPGSG KDYAGVFSDA GLTFTSSSGQ QTAQRAELQC PQPAA

REFERENCE   1:  119:137093

L4   ANSWER 27 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   124882-78-6  REGISTRY
CN   Complement C3f (human), N-L-tyrosyl- (9CI)  (CA INDEX NAME)
SQL  18
```

```
SEQ      1 YSSKITHRIH WESASLLR
             ====== =======
HITS AT:   5-17

REFERENCE   1:  112:53423

L4   ANSWER 28 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   112805-24-0  REGISTRY
CN   Complement C3f (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   16: PN: US20020160420 PAGE: 17 unclaimed sequence
CN   1: PN: US20020160532 PAGE: 7 claimed protein
CN   1: PN: US20020161181 PAGE: 7 claimed protein
CN   1: PN: WO02088717 SEQID: 1 claimed protein
CN   1: PN: WO03048775 SEQID: 1 claimed sequence
CN   L-Arginine, L-seryl-L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-
     histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-
     glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl-L-leucyl-
SQL  17

SEQ      1 SSKITHRIHW ESASLLR
             ======= ======
HITS AT:   4-16

REFERENCE   1:  139:35061

REFERENCE   2:  137:348843

REFERENCE   3:  137:348834

REFERENCE   4:  137:334909

REFERENCE   5:  137:334903

REFERENCE   6:  108:73458

L4   ANSWER 29 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   96162-42-4  REGISTRY
CN   Complement C3, pro- (human protein moiety reduced) (9CI)  (CA INDEX
     NAME)
CI   MAN
SQL  1641

SEQ      1 SPMYSIITPN ILRLESEETM VLEAHDAQGD VPVTVTVHDF PGKKLVLSSE
        51 KTVLTPATNH MGNVTFTIPA NREFKSEKGR NKFVTVQATF GTQVVEKVVL
       101 VSLQSGYLFI QTDKTIYTPG STVLYRIFTV NHKLLPVGRT VMVNIENPEG
       151 IPVKQDSLSS QNQLGVLPLS WDIPELVNMG QWKIRAYYEN SPQQVFSTEF
       201 EVKEYVLPSF EVIVEPTEKF YYIYNEKGLE VTITARFLYG KKVEGTAFVI
       251 FGIQDGEQRI SLPESLKRIP IEDGSGEVVL SRKVLLDGVQ NLRAEDLVGK
       301 SLYVSATVIL HSGSDMVQAE RSGIPIVTSP YQIHFTKTPK YFKPGMPFDL
       351 MVFVTNPDGS PAYRVPVAVQ GEDTVQSLTQ GDGVAKLSIN THPSQKPLSI
       401 TVRTKKQELS EAEQATRTMQ ALPYSTVGNS NNYLHLSVLR TELRPGETLN
       451 VNFLLRMDRA HEAKIRYYTY LIMNKGRLLK AGRQVREPGQ DLVVLPLSIT
       501 TDFIPSFRLV AYYTLIGASG QREVVADSVM VDVKDSCVGS LVVKSGQSED
       551 RQPVPGQQMT LKIEGDHGAR VVLVAVDKGV FVLNKKNKLT QSKIWDVVEK
       601 ADIGCTPGSG KDYAGVFSDA GLTFTSSSGQ QTAQRAELQC PQPAARRRRS
       651 VQLTEKRMDK VGKYPKELRK CCEDGMRENP MRFSCQRRTR FISLGEACKK
       701 VFLDCCNYIT ELRRQHARAS HLGLARSNLD EDIIAEENIV SRSEFPESWL
```

```
       751 WNVEDLKEPP KNGISTKLMN IFLKDSITTW EILAVSMSDK KGICVADPFE
       801 VTVMQDFFID LRLPYSVVRN EQVEIRAVLY NYRQNQELKV RVELLHNPAF
       851 CSLATTKRRH QQTVTIPPKS SLSVPYVIVP LKTGLQEVEV KAAVYHHFIS
       901 DGVRKSLKVV PEGIRMNKTV AVRTLDPERL GREGVQKEDI PPADLSDQVP
       951 DTESETRILL QGTPVAQMTE DAVDAERLKH LIVTPSGCGE QNMIGMTPTV
      1001 IAVHYLDETE QWEKFGLEKR QGALELIKKG YTQQLAFRQP SSAFAAFVKR
      1051 APSTWLTAYV VKVFSLAVNL IAIDSQVLCG AVKWLILEKQ KPDGVFQEDA
      1101 PVIHQEMIGG LRNNNEKDMA LTAFVLISLQ EAKDICEEQV NSLPGSITKA
      1151 GDFLEANYMN LQRSYTVAIA GYALAQMGRL KGPLLNKFLT TAKDKNRWED
      1201 PGKQLYNVEA TSYALLALLQ LKDFDFVPPV VRWLNEQRYY GGGYGSTQAT
      1251 FMVFQALAQY QKDAPDHQEL NLDVSLQLPS RSSKITHRIH WESASLLRSE
                                                   ====== =======
      1301 ETKENEGFTV TAEGKGQGTL SVVTMYHAKA KDQLTCNKFD LKVTIKPAPE
      1351 TEKRPQDAKN TMILEICTRY RGDQDATMSI LDISMMTGFA PDTDDLKQLA
      1401 NGVDRYISKY ELDKAFSDRN TLIIYLDKVS HSEDDCLAFK VHQYFNVELI
      1451 QPGAVKVYAY YNLEESCTRF YHPEKEDGKL NKLCRDELCR CAEENCFIQK
      1501 SDDKVTLEER LDKACEPGVD YVYKTRLVKV QLSNDFDEYI MAIEQTIKSG
      1551 SDEVQVGQQR TFISPIKCRE ALKLEEKKHY LMWGLSSDFW GEKPNLSYII
      1601 GKDTWVEHWP EEDECQDEEN QKQCQDLGAF TESMVVFGCP N
HITS AT:    1285-1297

REFERENCE   1:  102:180051

L4    ANSWER 30 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN    96162-41-3  REGISTRY
CN    Complement C3, prepro- (human protein moiety reduced) (9CI)  (CA
      INDEX NAME)
CI    MAN
SQL   1663

SEQ      1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ
        51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK
       101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF
       151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN
       201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG
       251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
       301 VLSRKVLLDG VQNLRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT
       351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL
       401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG
       451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL
       501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS
       551 VMVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
       601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS
       651 GQQTAQRAEL QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE
       701 NPMRFSCQRR TRFISLGEAC KKVFLDCCNY ITELRRQHAR ASHLGLARSN
       751 LDEDIIAEEN IVSRSEFPES WLWNVEDLKE PPKNGISTKL MNIFLKDSIT
       801 TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV RNEQVEIRAV
       851 LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI
       901 VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE
       951 RLGREGVQKE DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL
      1001 KHLIVTPSGC GEQNMIGMTP TVIAVHYLDE TEQWEKFGLE KRQGALELIK
      1051 KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA YVVKVFSLAV NLIAIDSQVL
      1101 CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD MALTAFVLIS
      1151 LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
      1201 RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP
      1251 PVVRWLNEQR YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL
      1301 PSRSSKITHR IHWESASLLR SEETKENEGF TVTAEGKGQG TLSVVTMYHA
                ==== =========
```

```
      1351 KAKDQLTCNK FDLKVTIKPA PETEKRPQDA KNTMILEICT RYRGDQDATM
      1401 SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD RNTLIIYLDK
      1451 VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
      1501 KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV
      1551 KVQLSNDFDE YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK
      1601 HYLMWGLSSD FWGEKPNLSY IIGKDTWVEH WPEEDECQDE ENQKQCQDLG
      1651 AFTESMVVFG CPN
HITS AT:   1307-1319

REFERENCE   1:  102:180051

L4   ANSWER 31 OF 31  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   96162-40-2  REGISTRY
CN   Complement C3 (human .alpha.-chain protein moiety reduced) (9CI)
     (CA INDEX NAME)
CI   MAN
SQL  992

SEQ      1 SVQLTEKRMD KVGKYPKELR KCCEDGMREN PMRFSCQRRT RFISLGEACK
        51 KVFLDCCNYI TELRRQHARA SHLGLARSNL DEDIIAEENI VSRSEFPESW
       101 LWNVEDLKEP PKNGISTKLM NIFLKDSITT WEILAVSMSD KKGICVADPF
       151 EVTVMQDFFI DLRLPYSVVR NEQVEIRAVL YNYRQNQELK VRVELLHNPA
       201 FCSLATTKRR HQQTVTIPPK SSLSVPYVIV PLKTGLQEVE VKAAVYHHFI
       251 SDGVRKSLKV VPEGIRMNKT VAVRTLDPER LGREGVQKED IPPADLSDQV
       301 PDTESETRIL LQGTPVAQMT EDAVDAERLK HLIVTPSGCG EQNMIGMTPT
       351 VIAVHYLDET EQWEKFGLEK RQGALELIKK GYTQQLAFRQ PSSAFAAFVK
       401 RAPSTWLTAY VVKVFSLAVN LIAIDSQVLC GAVKWLILEK QKPDGVFQED
       451 APVIHQEMIG GLRNNNEKDM ALTAFVLISL GEAKDICEEQ VNSLPGSITK
       501 AGDFLEANYM NLQRSYTVAI AGYALAQMGR LKGPLLNKFL TTAKDKNRWE
       551 DPGKQLYNVE ATSYALLALL QLKDFDFVPP VVRWLNEQRY YGGGYGSTQA
       601 TFMVFQALAQ YQKDAPDHQE LNLDVSLQLP SRSSKITHRI HWESASLLRS
                                                 ===== ========
       651 EETKENEGFT VTAEGKGQGT LSVVTMYHAK AKDQLTCNKF DLKVTIKPAP
       701 ETEKRPQDAK NTMILEICTR YRGDQDATMS ILDISMMTGF APDTDDLKQL
       751 ANGVDRYISK YELDKAFSDR NTLIIYLDKV SHSEDDCLAF KVHQYFNVEL
       801 IQPGAVKVYA YYNLEESCTR FYHPEKEDGK LNKLCRDELC RCAEENCFIQ
       851 KSDDKVTLEE RLDKACEPGV DYVYKTRLVK VQLSNDFDEY IMAIEQTIKS
       901 GSDEVQVGQQ RTFISPIKCR EALKLEEKKH YLMWGLSSDF WGEKPNLSYI
       951 IGKDTWVEHW PEEDECQDEE NQKQCQDLGA FTESMVVFGC PN
HITS AT:   636-648

REFERENCE   1:  102:180051

=> fil hom
FILE 'HOME' ENTERED AT 09:00:23 ON 29 AUG 2003
```